

## 5-Minute Journal Club: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer — Issue 3

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following statements is true regarding ESR1 mutations?**
  - ESR1 mutations are markers of active ER signaling and a mechanism of resistance to endocrine therapy that remains dependent on ER
  - Novel endocrine therapies show promising activity in the presence of ESR1 mutations and likely have increased potency compared to currently approved endocrine therapies
  - Future research involving ESR1 may focus on the effect of ESR1 mutation allele frequency, concurrent mutations and interaction with the tumor microenvironment
  - All of the above
- 2. In the Phase Ia/Ib EMBER trial of imlunestrant monotherapy, imlunestrant combined with abemaciclib, or imlunestrant combined with abemaciclib and an aromatase inhibitor (AI) for ER-positive, HER2-negative breast cancer, what was the overall response rate (ORR) in the monotherapy arm?**
  - 0%
  - 12%
  - 39%
  - 62%
- 3. In the Phase Ia/Ib EMBER trial of imlunestrant monotherapy, imlunestrant combined with abemaciclib, or imlunestrant combined with abemaciclib and an AI for ER-positive, HER2-negative breast cancer, what was the ORR in the triplet combination arm?**
  - 0%
  - 12%
  - 39%
  - 62%
- 4. In the Phase Ia/Ib EMBER trial of imlunestrant monotherapy, imlunestrant combined with abemaciclib, or imlunestrant combined with abemaciclib and an AI for ER-positive, HER2-negative breast cancer, what was the most commonly occurring adverse event in the combination arms?**
  - Hypertension
  - Thrombocytopenia
  - Gastrointestinal disorder
  - Hypokalemia
- 5. Which of the following statements best characterizes the study design of the TREAT circulating tumor DNA (ctDNA) trial?**
  - Observational study of adjuvant therapy outcomes with ctDNA monitoring for patients with ER-positive, HER2-negative breast cancer
  - Interventional study of therapeutic switching to elacestrant versus continuing adjuvant endocrine therapy for patients with ER-positive, HER2-negative breast cancer that tests ctDNA-positive but shows no evidence of progression on imaging
  - Interventional study of discontinuing adjuvant therapy for patients with ER-positive, HER2-negative breast cancer that tests ctDNA-negative and shows no evidence of progression on imaging